Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma

被引:14
作者
Fan, Tao [1 ]
Pan, Shize [1 ]
Yang, Shuo [2 ]
Hao, Bo [1 ]
Zhang, Lin [1 ]
Li, Donghang [1 ]
Geng, Qing [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Thorac Surg, Wuhan, Peoples R China
[2] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
中国国家自然科学基金;
关键词
interleukin; lung adenocarcinoma; biomarker; immunotherapy; immunologic landscape; TUMOR-CELLS; CANCER; EXPRESSION; RESISTANCE; INTERLEUKIN-11; IMMUNITY; IL-11; MICROENVIRONMENT; IMMUNOTHERAPY; MUTATIONS;
D O I
10.3389/fimmu.2021.693062
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukins (ILs) and interleukin receptors (ILRs) play important role in the antitumor immune response. However, the expression signature and clinical characteristics of the IL(R) family in lung adenocarcinoma (LUAD) remains unclear. The main purpose of this study was to explore the expression profile of IL(R) family genes and construct an IL(R)-based prognostic signature in LUAD. Five public datasets of 1,312 patients with LUAD were enrolled in this study. Samples from The Cancer Genome Atlas (TCGA) were used as the training set, and samples from the other four cohorts extracted from Gene Expression Omnibus (GEO) database were used as the validation set. Additionally, the profile of IL(R) family signature was explored, and the association between this signature and immunotherapy response was also analyzed. Meanwhile, the prognostic value was compared between this IL(R)-based signature and different immunotherapy markers. A signature based on five identified IL(R)s (IL7R, IL5RA, IL20RB, IL11, IL22RA1) was constructed using the TCGA dataset through univariate/multivariable Cox proportional hazards regression and least absolute shrinkage and selection operator (LASSO) Cox analysis. These cases with LUAD were stratified into high- and low-risk group according to the risk score. This signature showed a strong prognostic ability, which was verified by the five independent cohorts and clinical subtypes. The IL(R)-based models presented unique characteristics in terms of immune cell infiltration and immune inflammation profile in tumor microenvironment (TME). Biological pathway analysis confirmed that high-risk patients showed significant T- and B-cell immunosuppression and rapid tumor cell proliferation. More importantly, we researched the relationship between this IL(R)-based signature and immune checkpoints, tumor mutation burden (TMB), tumor purity and ploidy, and tumor immune dysfunction and exclusion (TIDE) score, which confirmed that this signature gave the best prognostic value. We first provided a robust prognostic IL(R)-based signature, which had the potential as a predictor for immunotherapy response to realize individualized treatment of LUAD.
引用
收藏
页数:17
相关论文
共 60 条
  • [1] The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy
    Abe, Yoshinori
    Tanaka, Nobuyuki
    [J]. BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [2] Trends and advances in tumor immunology and lung cancer immunotherapy
    Aldarouish, Mohanad
    Wang, Cailian
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35 : 1 - 13
  • [3] Current Approaches in NSCLC Targeting K-RAS and EGFR
    Aran, Veronica
    Omerovic, Jasminka
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (22)
  • [4] IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF
    Baird, Anne-Marie
    Gray, Steven G.
    O'Byrne, Kenneth J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (12) : 1908 - 1918
  • [5] Flip the coin: IL-7 and IL-7R in health and disease
    Barata, Joao T.
    Durum, Scott K.
    Seddon, Benedict
    [J]. NATURE IMMUNOLOGY, 2019, 20 (12) : 1584 - 1593
  • [6] Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
    Benci, Joseph L.
    Johnson, Lexus R.
    Choa, Ruth
    Xu, Yuanming
    Qiu, Jingya
    Zhou, Zilu
    Xu, Bihui
    Ye, Darwin
    Nathanson, Katherine L.
    June, Carl H.
    Wherry, E. John
    Zhang, Nancy R.
    Ishwaran, Hemant
    Hellmann, Matthew D.
    Wolchok, Jedd D.
    Kambayashi, Taku
    Minn, Andy J.
    [J]. CELL, 2019, 178 (04) : 933 - +
  • [7] Oncology Meets Immunology: The Cancer-Immunity Cycle
    Chen, Daniel S.
    Mellman, Ira
    [J]. IMMUNITY, 2013, 39 (01) : 1 - 10
  • [8] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [9] Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
    Devarakonda, Siddhartha
    Rotolo, Federico
    Tsao, Ming-Sound
    Lanc, Irena
    Brambilla, Elisabeth
    Masood, Ashiq
    Olaussen, Ken A.
    Fulton, Robert
    Sakashita, Shingo
    McLeer-Florin, Anne
    Ding, Keyue
    Le Teuff, Gwenael
    Shepherd, Frances A.
    Pignon, Jean-Pierre
    Graziano, Stephen L.
    Kratzke, Robert
    Soria, Jean-Charles
    Seymour, Lesley
    Govindan, Ramaswamy
    Michiels, Stefan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30) : 2995 - +
  • [10] TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
    Dixon, Karen O.
    Tabaka, Marcin
    Schramm, Markus A.
    Xiao, Sheng
    Tang, Ruihan
    Dionne, Danielle
    Anderson, Ana. C.
    Rozenblatt-Rosen, Orit
    Regev, Aviv
    Kuchroo, Vijay K.
    [J]. NATURE, 2021, 595 (7865) : 101 - +